337 related articles for article (PubMed ID: 25607951)
1. Metformin: a modulator of bevacizumab activity in cancer? A case report.
Indraccolo S; Randon G; Zulato E; Nardin M; Aliberti C; Pomerri F; Casarin A; Nicoletto MO
Cancer Biol Ther; 2015; 16(2):210-4. PubMed ID: 25607951
[TBL] [Abstract][Full Text] [Related]
2. Carboplatin-paclitaxel compared to Carboplatin-Paclitaxel-Bevacizumab in advanced or recurrent endometrial cancer: MITO END-2 - A randomized phase II trial.
Lorusso D; Ferrandina G; Colombo N; Pignata S; Pietragalla A; Sonetto C; Pisano C; Lapresa MT; Savarese A; Tagliaferri P; Lombardi D; Cinieri S; Breda E; Sabatucci I; Sabbatini R; Conte C; Cecere SC; Maltese G; Scambia G
Gynecol Oncol; 2019 Dec; 155(3):406-412. PubMed ID: 31677820
[TBL] [Abstract][Full Text] [Related]
3. VEGF-A levels in bevacizumab-treated breast cancer patients: a systematic review and meta-analysis.
Santos LV; Cruz MR; Lopes Gde L; Lima JP
Breast Cancer Res Treat; 2015 Jun; 151(3):481-9. PubMed ID: 25947646
[TBL] [Abstract][Full Text] [Related]
4. An exceptional overall survival using bevacizumab beyond progression in a patient with non-small cell lung cancer.
Roviello G; Francini E; Perrella A; Laera L; Mazzei MA; Guerrini S; Petrioli R
Cancer Biol Ther; 2015; 16(12):1720-5. PubMed ID: 26418066
[TBL] [Abstract][Full Text] [Related]
5. Early PET/CT scan is more effective than RECIST in predicting outcome of patients with liver metastases from colorectal cancer treated with preoperative chemotherapy plus bevacizumab.
Lastoria S; Piccirillo MC; Caracò C; Nasti G; Aloj L; Arrichiello C; de Lutio di Castelguidone E; Tatangelo F; Ottaiano A; Iaffaioli RV; Izzo F; Romano G; Giordano P; Signoriello S; Gallo C; Perrone F
J Nucl Med; 2013 Dec; 54(12):2062-9. PubMed ID: 24136935
[TBL] [Abstract][Full Text] [Related]
6. New options for integrating antiangiogenic therapy and platinum-based first-line chemotherapy for advanced non-small-cell lung cancer.
Manegold C
Clin Lung Cancer; 2008; 9 Suppl 3():S100-8. PubMed ID: 19419923
[TBL] [Abstract][Full Text] [Related]
7. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
8. PET/CT in the evaluation of response to treatment of liver metastases from colorectal cancer with bevacizumab and irinotecan.
Goshen E; Davidson T; Zwas ST; Aderka D
Technol Cancer Res Treat; 2006 Feb; 5(1):37-43. PubMed ID: 16417400
[TBL] [Abstract][Full Text] [Related]
9. [A case of multiple lung and liver metastases from colon cancer treated with clinical benefit by hepatic arterial infusion chemotherapy plus cetuximab mono-therapy after standard chemotherapy failure].
Osawa G; Yoshimatsu K; Yokomizo H; Otani T; Yano Y; Itagaki H; Matsumoto A; Fujimoto T; Umehara A; Ogawa K
Gan To Kagaku Ryoho; 2010 Nov; 37(12):2526-8. PubMed ID: 21224628
[TBL] [Abstract][Full Text] [Related]
10. Bevacizumab in Patients with Nonsquamous Non-Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study.
Besse B; Le Moulec S; Mazières J; Senellart H; Barlesi F; Chouaid C; Dansin E; Bérard H; Falchero L; Gervais R; Robinet G; Ruppert AM; Schott R; Léna H; Clément-Duchêne C; Quantin X; Souquet PJ; Trédaniel J; Moro-Sibilot D; Pérol M; Madroszyk AC; Soria JC
Clin Cancer Res; 2015 Apr; 21(8):1896-903. PubMed ID: 25614446
[TBL] [Abstract][Full Text] [Related]
11. Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study.
Leslie KK; Filiaci VL; Mallen AR; Thiel KW; Devor EJ; Moxley K; Richardson D; Mutch D; Secord AA; Tewari KS; McDonald ME; Mathews C; Cosgrove C; Dewdney S; Casablanca Y; Jackson A; Rose PG; Zhou X; McHale M; Lankes H; Levine DA; Aghajanian C
Gynecol Oncol; 2021 Apr; 161(1):113-121. PubMed ID: 33541735
[TBL] [Abstract][Full Text] [Related]
12. EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.
Otsuka K; Hata A; Takeshita J; Okuda C; Kaji R; Masago K; Fujita S; Katakami N
Cancer Chemother Pharmacol; 2015 Oct; 76(4):835-41. PubMed ID: 26349474
[TBL] [Abstract][Full Text] [Related]
13. Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer.
Wagner AD; Thomssen C; Haerting J; Unverzagt S
Cochrane Database Syst Rev; 2012 Jul; (7):CD008941. PubMed ID: 22786517
[TBL] [Abstract][Full Text] [Related]
14. Bevacizumab as first-line treatment in HER2-negative advanced breast cancer: pros and cons.
Sini V; Cassano A; Corsi D; De Laurentiis M; Gamucci T; Mauri M; Naso G; Roselli M; Ruggeri EM; Tonini G; Vici P; Zampa G; Marchetti P
Tumori; 2016 Oct; 102(5):472-480. PubMed ID: 27647231
[TBL] [Abstract][Full Text] [Related]
15. One patient with metastastic colorectal cancer successfully treated by combination of targeted agents after failure of chemotherapy.
Xia LP; Wu PH; Xia JC; Zhang B; Guan ZZ; Wan DS; Guo GF; Zeng YX
Chin J Cancer; 2010 Dec; 29(12):1023-8. PubMed ID: 21114924
[TBL] [Abstract][Full Text] [Related]
16. Combined Targeted Therapies for First-line Treatment of Metastatic Triple Negative Breast Cancer-A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib.
Symonds L; Linden H; Gadi V; Korde L; Rodler E; Gralow J; Redman M; Baker K; Wu QV; Jenkins I; Kurland B; Garrison M; Smith J; Anderson J; Van Haelst C; ; Specht J
Clin Breast Cancer; 2019 Apr; 19(2):e283-e296. PubMed ID: 30737173
[TBL] [Abstract][Full Text] [Related]
17. Randomized phase II-III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial†.
Pujol JL; Lavole A; Quoix E; Molinier O; Souquet PJ; Barlesi F; Le Caer H; Moro-Sibilot D; Fournel P; Oster JP; Chatellain P; Barre P; Jeannin G; Mourlanette P; Derollez M; Herman D; Renault A; Dayen C; Lamy PJ; Langlais A; Morin F; Zalcman G;
Ann Oncol; 2015 May; 26(5):908-914. PubMed ID: 25688059
[TBL] [Abstract][Full Text] [Related]
18. Clinical and biological significance of vascular endothelial growth factor in endometrial cancer.
Kamat AA; Merritt WM; Coffey D; Lin YG; Patel PR; Broaddus R; Nugent E; Han LY; Landen CN; Spannuth WA; Lu C; Coleman RL; Gershenson DM; Sood AK
Clin Cancer Res; 2007 Dec; 13(24):7487-95. PubMed ID: 18094433
[TBL] [Abstract][Full Text] [Related]
19. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.
Lee MS; Ryoo BY; Hsu CH; Numata K; Stein S; Verret W; Hack SP; Spahn J; Liu B; Abdullah H; Wang Y; He AR; Lee KH;
Lancet Oncol; 2020 Jun; 21(6):808-820. PubMed ID: 32502443
[TBL] [Abstract][Full Text] [Related]
20. Exploiting FAsting-mimicking Diet and MEtformin to Improve the Efficacy of Platinum-pemetrexed Chemotherapy in Advanced LKB1-inactivated Lung Adenocarcinoma: The FAME Trial.
Vernieri C; Signorelli D; Galli G; Ganzinelli M; Moro M; Fabbri A; Tamborini E; Marabese M; Caiola E; Broggini M; Hollander L; Gallucci R; Vandoni G; Gavazzi C; Triulzi T; Colombo MP; Rizzo AM; Corsetto PA; Pruneri G; de Braud F; Sozzi G; Torri V; Garassino MC
Clin Lung Cancer; 2019 May; 20(3):e413-e417. PubMed ID: 30617039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
